Company Filing History:
Years Active: 2025
Title: Agostino Cirillo: Innovator in Solubilized Apyrases
Introduction
Agostino Cirillo, an inventive mind based in Basel, Switzerland, has made a significant contribution to the field of biotechnology. With one patent under his name, his work showcases the importance of innovation in therapeutic applications. Cirillo's research focuses on solubilized apyrase polypeptides, aiming to enhance medical treatments and improve patient outcomes.
Latest Patents
Cirillo's notable patent, titled "Solubilized apyrases, methods and use," outlines critical advancements in the application of apyrase polypeptides. This patent includes solubilized apyrase polypeptides and the nucleotides encoding them, which are essential for pharmaceutical compositions. The therapeutic uses highlighted in the patent indicate significant potential in preventing or treating tissue damage through the administration of solubilized apyrase polypeptides or relevant medicinal compositions. Additionally, the patent elucidates methods for effectively producing these innovative polypeptides.
Career Highlights
Agostino Cirillo is affiliated with Novartis AG, a leading global healthcare company. His role within Novartis reflects his commitment to advancing therapeutic solutions through innovative research. With a focus on practical applications of biotechnology, Cirillo aims to develop effective treatments that can change lives.
Collaborations
Cirillo collaborates with Boerje Haraldsson, showcasing a partnership that enhances the breadth of their research. Working alongside experienced professionals is crucial in driving forward the innovative aspects of their projects and ensuring the successful application of their findings in the medical field.
Conclusion
Agostino Cirillo exemplifies the spirit of innovation through his dedicated work in biotechnology. His landmark patent on solubilized apyrases represents not just a personal achievement, but a step forward in medical science that could significantly impact patient care. As he continues his work at Novartis AG, the scientific community eagerly anticipates further advancements from Cirillo and his collaborators.